Loss of VGLL4 suppresses tumor PD-L1 expression and immune evasion

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Immune checkpoint inhibitors targeting PD-L1/PD-1 are crucial cancer therapies.
• Understanding PD-L1 regulation is vital for improving treatment efficacy.
• The role of VGLL4 in anti-tumor immunity was previously unknown.

Purpose of the Study:

• To investigate the role of VGLL4 in anti-tumor immunity.
• To elucidate the regulatory mechanisms of PD-L1 expression involving VGLL4 and YAP.

Main Methods:

• Murine syngeneic models were used to study tumor regression upon Vgll4 disruption.
• Protein-protein interactions and degradation pathways were analyzed (VGLL4-IRF2BP2).
• Transcriptional regulation of PD-L1 was assessed, including the role of IRF2 and YAP-mediated suppression via miR-130a.

Main Results:

• Disruption of Vgll4 led to significant T cell-mediated tumor regression.
• VGLL4 deficiency reduced PD-L1 expression in tumor cells.
• VGLL4 stabilizes IRF2BP2, preventing IRF2 binding to the PD-L1 promoter.
• YAP suppresses IFNγ-inducible PD-L1 expression by downregulating VGLL4 and IRF1 via miR-130a.

Conclusions:

• VGLL4 is a critical regulator of PD-L1 expression in tumor cells.
• VGLL4 and YAP play central roles in modulating tumor immunity.
• Targeting the VGLL4/YAP pathway may offer novel combinatorial strategies for cancer immunotherapy.